JAMA Oncology – Cancer Treatment, Genetics, & Prevention

Research

Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
Maria E. Cabanillas, MD; et al.

Original Investigation
open access has multimedia
Maria E. Cabanillas, MD; et al.

Editorial
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma
Kartik Sehgal, MD; et al.

Original Investigation

Kartik Sehgal, MD; et al.

Editorial
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma
Nathalie Gaspar, MD, PhD; et al.

Original Investigation
open access
Nathalie Gaspar, MD, PhD; et al.

Opinion

Cancer Drug Access and Innovation Under the Inflation Reduction Act
Stacie B. Dusetzina, PhD; et al.

Viewpoint

Stacie B. Dusetzina, PhD; et al.
Impacts of Immunotherapy on Patients With Aggressive Thyroid Carcinomas
Alfred King-yin Lam, MBBS, MD, PhD

Editorial

Alfred King-yin Lam, MBBS, MD, PhD
Implementing Resource-Stratified Guidelines in LMICs
Shweta Baral, MD

Viewpoint

Shweta Baral, MD

Clinical Review & Education

Hairy Kidneys and Sclerotic Bone Lesions
Juan Esteban Velez-Hernandez, MD; et al.

JAMA Oncology Clinical Challenge
has active quiz
Juan Esteban Velez-Hernandez, MD; et al.
Endometrial Cancer Classification and Management in the Molecular Subtyping Era
Anjelica Hodgson, MD; et al.

JAMA Oncology Diagnostic Test Interpretation
has active quiz
Anjelica Hodgson, MD; et al.
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs
Jonathan M. Loree, MD, MSc; et al.

Special Communication
has active quiz
Jonathan M. Loree, MD, MSc; et al.